Wednesday, 2 April 2025
24.1 C
Singapore
31.1 C
Thailand
21.9 C
Indonesia
26.6 C
Philippines

Bioptimus secures US$41M to create groundbreaking AI for biology

French startup Bioptimus raises US$41M to develop AI that simulates biological processes, driving medical, biotech, and cosmetic innovations.

A French AI startup, Bioptimus, has raised US$41 million to develop an innovative foundational AI model explicitly designed for biology. This cutting-edge technology aims to simulate biological processes and drive medical, pharmaceutical, and even cosmetic discoveries.

A new era of biology

Just as OpenAIโ€™s ChatGPT revolutionised text-based interactions, Bioptimus plans to transform the understanding of biology by creating a model capable of simulating biological systems. The model will leverage raw data from molecules to entire organisms, enabling scientists to predict disease outcomes and develop more effective treatments.

Jean-Philippe Vert, co-founder and CEO of Bioptimus, describes the technology as โ€œthe GPT of biologyโ€ but with a focus on biological simulations instead of text generation. This approach could redefine how researchers analyse and interpret biological data, pushing the boundaries of science in unprecedented ways.

โ€œEssentially, itโ€™s like the GPT of biology โ€” but instead of generating text, weโ€™re simulating biology,โ€ Vert explained.

Franceโ€™s rise as an AI powerhouse

France is quickly becoming a hub for AI innovation. Over the past 18 months, several generative AI startups, including Mistral AI, Hugging Face, and H, have secured significant investments. Bioptimus, founded just last year, has already raised US$76 million in total funding, including a US$35 million seed round shortly after its launch.

Bioptimus benefits from the expertise of its six co-founders, such as Rodolphe Jenatton, who previously worked as a senior research scientist at Amazon and Google. Vert himself is the chief R&D officer at Owkin, another French AI-focused biotech unicorn. Owkin, a pioneer in using AI for drug discovery, has amassed a wealth of multimodal patient data, which Bioptimus is now utilising to train its foundational model.

Rather than embedding the foundational model development within Owkin, the team created Bioptimus as an independent entity. This approach allows for a focused effort on building large-scale foundational models while maintaining flexibility in securing resources like data and computing power.

Expanding horizons

Since its inception, Bioptimus has launched H-Optimus-0, an open-source foundation model for pathology, trained on millions of images to advance disease diagnosis and research, including cancer. With its latest funding, the company plans to enhance its AI platform using a broader range of data sources and develop partnerships with pharmaceutical and biotech companies.

A multi-modal foundation model, set to launch later this year, will span the entire biological spectrum and offer applications across various industries. Vert believes the model will pave the way for breakthroughs beyond healthcare, unlocking biological discoveries in unimaginable ways.

โ€œBeyond pharmaceuticals, this model will unlock limitless possibilities across many other industries, driving biological discoveries in ways we are only beginning to imagine,โ€ Vert noted.

The US$41 million funding round was led by Cathay Innovation, a U.S.-based company, with contributions from Sofinnova Partners, Bpifrance, Andera Partners, Hitachi Ventures, and others. This injection of capital solidifies Bioptimusโ€™s position as a frontrunner in developing AI tools for biology.

Hot this week

Instagram introduces new speed-up feature for Reels

Instagram now lets you watch Reels at double speed, just like TikTok. The new feature helps you get through longer videos faster and easier.

Most consumers now back up their data, but cloud storage limits push shift to hybrid solutions

87% of people now back up their data, but cloud limits and rising costs are driving a shift to hybrid storage solutions.

Apple prepares for M5 iPad Pro and MacBook Pro release

Apple is set to launch the M5 iPad Pro and MacBook Pro in late 2024, with the M6 models expected to introduce an in-house modem in 2027.

AMD Ryzen 7 9800X3D processors failing too soon, users report

Reports of AMD Ryzen 7 9800X3D CPU failures are growing, with over 100 cases linked to ASRock motherboards. Users suspect voltage issues.

Intel remains on course for next-gen CPUs

Intel CEO Lip-Bu Tan confirms that next-gen CPUs, including Panther Lake and Nova Lake, remain on track, with Panther Lake arriving in 2025.

These robot vacuums are getting smarter with Apple Home support

Appleโ€™s iOS 18.4 update adds Matter support for robot vacuums, enabling control via Apple Home. Roborock, iRobot, and Ecovacs are updating their devices.

Gmail introduces easier encryption for business emails

Google introduces a new encryption model for Gmail, making it easier for businesses to send secure emails without special software or certificates.

Nothing Phone (3a) Pro review: A mid-range marvel with standout zoom

Nothing Phone (3a) Pro blends standout design, powerful zoom camera, and smart features, making it a top choice in the mid-range segment.

Vivo challenges iPhone 16 Pro Max with X200 Ultraโ€™s video stability

Vivoโ€™s X200 Ultra teaser compares video stability with the iPhone 16 Pro Max, promising top-tier camera upgrades and advanced stabilisation.

Related Articles